p53 DNA binding missense mutants continue to be an expanding area of research for designing new therapies targeted towards stabilization and reactivation of the protein’s diverse critical pathways for tumor suppression (Reviewed in [38–41]). The gene discussed is TP53; the disease is neoplasm.